Continuous itaconic acid production by immobilized biocatalysts.

H. Kautola,Nikolay Vassilev,Y. Linko

DOI: https://doi.org/10.1016/0168-1656(90)90079-Q

IF: 3.595

1990-03-01

Journal of Biotechnology

Abstract:

What problem does this paper attempt to address?

Acute Hyperglycemia-Induced Injury in Myocardial Infarction

Martino Pepe,Francesco Addabbo,Annagrazia Cecere,Rocco Tritto,Gianluigi Napoli,Palma Luisa Nestola,Plinio Cirillo,Giuseppe Biondi-Zoccai,Salvatore Giordano,Marco Matteo Ciccone

DOI: https://doi.org/10.3390/ijms25158504

2024-08-04

Abstract:Acute hyperglycemia is a transient increase in plasma glucose level (PGL) frequently observed in patients with ST-elevation myocardial infarction (STEMI). The aim of this review is to clarify the molecular mechanisms whereby acute hyperglycemia impacts coronary flow and myocardial perfusion in patients with acute myocardial infarction (AMI) and to discuss the consequent clinical and prognostic implications. We conducted a comprehensive literature review on the molecular causes of myocardial damage driven by acute hyperglycemia in the context of AMI. The negative impact of high PGL on admission recognizes a multifactorial etiology involving endothelial function, oxidative stress, production of leukocyte adhesion molecules, platelet aggregation, and activation of the coagulation cascade. The current evidence suggests that all these pathophysiological mechanisms compromise myocardial perfusion as a whole and not only in the culprit coronary artery. Acute hyperglycemia on admission, regardless of whether or not in the context of a diabetes mellitus history, could be, thus, identified as a predictor of worse myocardial reperfusion and poorer prognosis in patients with AMI. In order to reduce hyperglycemia-related complications, it seems rational to pursue in these patients an adequate and quick control of PGL, despite the best pharmacological treatment for acute hyperglycemia still remaining a matter of debate.
Expression Profiles of Long Noncoding RNAs in Cardiac Stem Cells under Hyperglycemic Conditions

Wei Liu,Yujie Pu,Chao Wang,Chuanlong Gu,Xiaoming Zhang

DOI: https://doi.org/10.1016/j.ijcard.2016.08.028

IF: 4.039

2016-01-01

International Journal of Cardiology

Abstract:From previous reports, the incidence of ischaemic heart disease and acute myocardial infarction is greater in people with diabetes than in nondiabetic individuals, and has suffered from a higher incidence of mortality [ 1 Ahmed B. Davis H.T. Laskey W.K. In-hospital mortality among patients with type 2 diabetes mellitus and acute myocardial infarction: results from the national inpatient sample, 2000–2010. J. Am. Heart Assoc. 2014; 3 Crossref Scopus (36) Google Scholar , 2 Koek H.L. Soedamah-Muthu S.S. Kardaun J.W. Gevers E. de Bruin A. Reitsma J.B. et al. Short- and long-term mortality after acute myocardial infarction: comparison of patients with and without diabetes mellitus. Eur. J. Epidemiol. 2007; 22: 883-888 Crossref PubMed Scopus (46) Google Scholar , 3 Rousan T.A. Pappy R.M. Chen A.Y. Roe M.T. Saucedo J.F. Impact of diabetes mellitus on clinical characteristics, management, and in-hospital outcomes in patients with acute myocardial infarction (from the NCDR). Am. J. Cardiol. 2014; 114: 1136-1144 Abstract Full Text Full Text PDF PubMed Scopus (35) Google Scholar ]. Meanwhile, the risk of post-myocardial infarction death is also increased in diabetic patients compared to those without diabetes. Of 157,142 people with an MI in England and Wales between 2003–2006, the relative risk of death or recurrence of MI for those with diabetes in the first 90 days was 1.3 (95%CI: 1.26–1.33) crude rates and 1.16 (95%CI: 1.1–1.2) when controlling for age, gender, heart failure and surgery for MI compared with those without diabetes [ [4] Brophy S. Cooksey R. Gravenor M.B. Weston C. Macey S.M. John G. et al. Population based absolute and relative survival to 1 year of people with diabetes following a myocardial infarction: a cohort study using hospital admissions data. BMC Public Health. 2010; 10: 338 Crossref PubMed Scopus (15) Google Scholar ]. However, the mechanisms associated with diabetes-induced low myocardial regeneration and repair capability after myocardial injury remain elusive.
Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome

Angelo Avogaro,Enzo Bonora,Agostino Consoli,Stefano Del Prato,Stefano Genovese,Francesco Giorgino

DOI: https://doi.org/10.1177/1479164119845612

2019-05-02

Diabetes and Vascular Disease Research

Abstract:Diabetes is a common comorbidity in patients hospitalized for an acute coronary syndrome event, and prevalence is increasing. Among patients hospitalized with acute myocardial infarction, diabetes can be an independent predictor of mortality and new cardiovascular events; both short- and long-term outcomes are worse for patients with diabetes relative to those without, and undiagnosed diabetes is associated with greater mortality. The impact of glycemic control on cardiovascular outcomes and the best approach to treat hyperglycemia upon hospital admission for acute coronary syndrome in patients with or without known diabetes remain open questions. This review assesses available evidence for hyperglycemia management at the time of admission for acute coronary syndrome and, thereafter, finds that (1) admission plasma glucose plays a role in predicting adverse events, especially in patients with unknown diabetes; (2) glycated haemoglobin is a likely predictor of events in patients with unknown diabetes; and (3) hypoglycemia at the time of acute myocardial infarction hospital admission is an important predictor for mortality in patients with and without diabetes. Whether glucose-targeted insulin and glucose infusion have advantages over glucose–insulin–potassium infusion remains controversial. Evidence for the effect of novel glucose-lowering agents used at the time of an acute cardiovascular event is limited and requires more dedicated studies.

endocrinology & metabolism,peripheral vascular disease
Management of Hyperglycemia in Acute Ischemic Stroke

Lauren Baker,Rattan Juneja,Askiel Bruno

DOI: https://doi.org/10.1007/s11940-011-0143-8

IF: 2

2011-08-23

Current Treatment Options in Neurology

Abstract:Opinion statementThere is considerable clinical evidence that hyperglycemia at the onset of acute ischemic stroke may negatively impact not only acute morbidity but also brain recovery. Establishing hyperglycemia treatment protocols is challenging, given the variation among patients and acute stroke care settings. Relatively few randomized trials have examined glycemic control protocols in this population, and there is not yet any clear evidence that “correcting” hyperglycemia in patients with acute stroke leads to better functional outcomes. Intensification of glucose regimens, using lower glucose targets, leads to more hypoglycemic events, but the immediate and long-term impact of these events on the acutely ischemic brain is unknown. It is reasonable to treat patients with acute ischemic stroke according to the American Diabetes Association inpatient glycemic control guidelines, initiating therapy to achieve glucose targets of 140 to 180 mg/dL if fasting glucose is greater than 140 mg/dL or random glucose is consistently higher than 180 mg/dL. Lower glucose targets (<140 mg/dL) may be appropriate for patients with well-controlled diabetes and those with stress hyperglycemia who were not known to be diabetic before admission, but glucose levels less than 80 mg/dL should be avoided. Patients who present with extreme or persistent hyperglycemia, are critically ill, or who are treated with thrombolytic therapy should be started on an established and standardized intravenous insulin protocol to improve blood glucose control for at least the first 24 to 48 h of hospitalization. They should then be transitioned to a subcutaneous insulin regimen that includes basal long-acting insulin along with correction rapid-acting insulin for glucose that is out of range. Prandial (meal) insulin should be added for patients who are eating; this would preferably be a rapid-acting insulin analogue that can be administered immediately before or after the meal. Caution and close glucose monitoring are necessary, especially for patients prone to hypoglycemia, such as those with type 1 diabetes mellitus or hepatic or renal impairment, or those on complicated feeding regimens.

clinical neurology
Importance of measuring glycosylated hemoglobin in patients with myocardial infarction and known diabetes mellitus

Joshua M Stolker,Dazhong Sun,Darcy G Conaway,Philip G Jones,Frederick A Masoudi,Pamela N Peterson,Harlan M Krumholz,Mikhail Kosiborod,John A Spertus

DOI: https://doi.org/10.1016/j.amjcard.2009.12.010

2010-04-15

Abstract:Although medical co-morbidities commonly affect clinical outcomes after acute myocardial infarction (AMI), current performance measures of AMI quality focus exclusively on the management of the AMI itself. However, patients with AMIs frequently present with other co-morbidities, such as diabetes mellitus (DM), that also warrant assessment and management. To date, the quality of DM evaluation in patients presenting with AMIs has not been described. From January 2003 to June 2004, the Prospective Registry Evaluating Myocardial Infarction Patients: Events and Recovery-Quality Improvement (PREMIER-QI) enrolled 3,953 patients with AMIs at 19 centers in the United States. The frequency of glycosylated hemoglobin (HbA(1c)) assessment, either during the hospitalization or documented in the chart from the preceding 3 months, was prospectively evaluated. Among 1,168 patients with AMIs with preexisting DM, only 47% had recent HbA(1c) levels available, with marked variability in HbA(1c) assessment among hospitals (range 7% to 81%). Among those with available HbA(1c) levels, 39% had good control (HbA(1c) <7%), 36% had suboptimal control (HbA(1c) 7% to 9%), and 25% had poor control (HbA(1c) >9%). Patients with suboptimal and poor control were more likely to have their DM treatment intensified than those without HbA(1c) assessment (for HbA(1c) 7% to 9%, rate ratio 1.38, 95% confidence interval 1.03 to 1.85; for HbA(1c) >9%, rate ratio 2.20, 95% confidence interval 1.68 to 2.88). Similarly, patients with DM who had HbA(1c) measured were more likely to receive instructions on DM disease management before discharge. In conclusion, the assessment of chronic glycemic control is highly variable among patients with AMIs and DM. Because much of this variability occurs at the hospital level, the evaluation of DM control could represent an additional quality indicator and an opportunity to advance patient-centered AMI care.
Potential value of triple antiplatelet therapy for secondary stroke prevention.

S. Jonas,G. Grieco

DOI: https://doi.org/10.1161/01.STR.0000092896.70446.87

IF: 10.17

2003-10-01

Stroke

Abstract:To the Editor: We present (see the Table) our meta-analyses of the effects of antiplatelet regimens on the end point of stroke in long-term secondary stroke prevention trials (CAPRIE1 and AAASPS2; references for all other trials are in antiplatelet trialist articles3,4). Statistically significant results are indicated by their 95% confidence intervals (CI). That aspirin (ASA) is better than placebo is well demonstrated statistically ( P <0.001), but the benefit is modest: a relative risk reduction (RRR) of 16%. The benefit from dipyridamole (DP) monotherapy appears to be similar to that of ASA. The ADP receptor antagonists (ADPRAs) clopidogrel and ticlopidine are perhaps somewhat more effective …
[The Prognostic Value of Admission Blood Glucose Level in Acute Myocardial Infarction after Primary Percutaneous Coronary Intervention].

Lei Li,Yan-hong Guo,Wei Gao,Li-jun Guo

DOI: https://doi.org/10.3760/j.issn:0578-1426.2007.01.010

2007-01-01

Abstract:OBJECTIVE:To evaluate the predictive value of the admission blood glucose level for in-hospital mortality and major adverse cardiac events (MACE) rate in patients with acute myocardial infarction (AMI) who underwent primary percutaneous coronary intervention (PCI).METHODS:The cohort study comprised 312 consecutive patients with AMI who underwent primary PCI within 24 hours after the onset of chest pain, including diabetic patients and non-diabetic patients. According to the levels of the admission glucose (11 mmol/L), these patients were divided into two groups: a high admission glucose group and a normal admission glucose group.RESULTS:There were no significant differences in age, hypertension, hyperlipidemia, LVEF, CK-MB and hypersensitive C reactive protein. PCI success rate was similar in both groups (P > 0.05). The in-hospital mortality and 180-day MACE rate were significantly higher in patients with high concentration of admission glucose than in patients with normal concentration (18.2% vs 3.0% P < 0.001, 25% vs 12.7%, P = 0.047). However, there was no significant difference in mortality and 180-day MACE rate between diabetic and non-diabetic patients. Binary logistic regression analysis indicated that high concentration of the admission glucose remained an independent predicator of the in-hospital mortality (OR 5.15, 95% CI 1.74 - 15.28, P = 0.003) and higher occurrence rate of 180-day MACE (OR 2.84, 95% CI 1.18 - 6.83, P = 0.019).CONCLUSIONS:High concentration of admission glucose, but not the diagnosis of diabetes, was an important predictor for in-hospital mortality and 180-day MACE rate in patients with AMI who underwent primary PCI.
Hyperglycemia Affects the Prognosis of Acute Myocardial Infarction

Jin ZHANG,Ting-song LIU,Rui-hua CHEN,Shi-sen JIANG,Jian-bin GONG,Qi-gao ZHANG,Li-jun WANG,Yong-ping PENG,Xun-min CHEN

DOI: https://doi.org/10.3969/j.issn.1008-8199.2008.11.024

2008-01-01

Abstract:Objective: To observe the influence of admission blood glucose on the prognosis of acute myocardial infarction(AMI) in patients without a history of diabetes mellitus during hospital stay.Methods: A total of 737 AMI patients without a history of diabetes mellitus were divided into 3 groups according to the level of admission blood glucose(BG): GroupⅠ(n=357) with BG6.1 mmol/L,Group Ⅱ(n=228) with BG between 6.1 and 7.8 mmol/L,and Group Ⅲ(n=152) with BG 7.8 mmol/L.The basic clinical data,infarction sites,incidence of main complications and case-fatality were compared among the three groups.Results: In those with higher BG,there were more females,older in age,and with fewer initial angina symptoms,faster heart rate and lower blood pressure.The incidences of heart failure,severe arrhythmia and cardiac shock and case-fatality were obviously higher in Group Ⅱ than in Ⅰ(P0.05).And the rate of main complications and case-fatality were significantly higher in Group Ⅲ than in the other two during the hospital stay(P 0.01 and P0.05).No statistically significant differences were observed in the infarction sites among the three groups(P 0.05).Conclusion: Non-diabetic AMI patients with elevated admission BG had higher incidences of heart failure,severe arrhythmia and cardiac shock,higher case-fatality and worse prognosis during the hospital stay.
Relationship Between Hyperglycaemia at Admission and Prognosis in Patients with Acute Myocardial Infarction: a Retrospective Cohort Study

Linlin Liu,Jun Qian,Wenwen Yan,Xuebo Liu,Ya Zhao,Lin Che

DOI: https://doi.org/10.1136/pmj-2021-141454

2022-01-01

Postgraduate Medical Journal

Abstract:Background The optimal threshold of hyperglycaemia at admission for identifying high-risk individuals in patients with acute myocardial infarction (AMI) and its impact on clinical prognosis are still unclear. Methods We retrospectively reviewed 2027 patients with AMI admitted from June 2001 to December 2012 in the 'Medical Information Mart for Intensive Care III' database. The significant cut-off values of admission blood glucose (Glucose_0) for predicting hospital mortality in patients with AMI with and without diabetes were obtained from the receiver operating characteristic (ROC) curve, then patients were assigned to hyperglycaemia and non-hyperglycaemia groups based on corresponding cut-off values. The primary endpoints were the hospital and 1-year mortality. Results Among 2027 patients, death occurred in 311 patients (15.3%). According to the ROC curve, the significant cut-off values of Glucose_0 to predict hospital mortality were 224.5 and 139.5 mg/dL in patients with diabetes and without diabetes, respectively. The crude hospital and 1-year mortality of the hyperglycaemia subgroup were higher than the corresponding non-hyperglycaemia group (p< 0.01). After adjustment, regardless of the state of diabetes, hyperglycaemia at admission was related to significantly increased hospital mortality in patients with AMI. For patients with AMI without diabetes, hyperglycaemia at admission was positively correlated with the increase of 1-year mortality (HR, 1.47; 95% CI 1.18 to 1.82; p=0.001). Nevertheless, this trend disappeared in those with diabetes (HR, 1.35; 95% CI 0.93 to 1.95; p=0.113). Conclusion Hyperglycaemia at admission was an independent predictor for mortality during hospitalisation and at 1-year in patients with AMI, especially in patients without diabetes.
Lowering glucose to prevent adverse cardiovascular outcomes in a critical care setting

Antonio Ceriello,Stuart W Zarich,Roberto Testa

DOI: https://doi.org/10.1016/j.jacc.2008.09.054

2009-02-03

Abstract:High admission blood glucose levels after acute myocardial infarction are common and associated with an increased risk of death in patients with or without diabetes. Hyperglycemia is associated with altered myocardial blood flow and energetics and can lead to a pro-oxidative/proinflammatory state. The use of intensive insulin treatment has shown superior benefits in the treatment of hyperglycemia versus glucose-insulin-potassium infusion, particularly in critical care settings.
Longitudinal trajectories of blood glucose and 30-day mortality in patients with diabetes mellitus combined with acute myocardial infarction: A retrospective cohort analysis of the MIMIC database

Bowen Deng,Qingcheng Liu,Liang Qiao,Shun Lv

DOI: https://doi.org/10.1371/journal.pone.0307905

IF: 3.7

2024-09-14

PLoS ONE

Abstract:Although blood glucose changes have been suggested to be a potential better target for clinical control than baseline blood glucose levels, the association of blood glucose changes with the prognosis in acute myocardial infarction (AMI) patients with diabetes mellitus (DM) is unclear. Herein, this study aimed to investigate association of short-term longitudinal trajectory of blood glucose with 30-day mortality in this population. Data of AMI patients with DM were extracted from the Medical Information Mart for Intensive Care (MIMIC) database in 2003–2019 in this retrospective cohort study. The latent growth mixture modeling (LGMM) model was utilized to classify the 24-hour longitudinal trajectory of blood glucose of the patients. Kaplan-Meier (KM) curve was drawn to show 30-day mortality risk in patients with different trajectory classes. Univariate and multivariate Cox regression analyses were employed to explore the association of longitudinal trajectory of blood glucose within 24 hours after the ICU admission with 30-day mortality. Also, subgroups analysis of age, gender, and AMI types was performed. The evaluation indexes were hazard ratios (HRs) and 95% confidence intervals (CIs). Among 1,523 eligible patients, 227 (14.9%) died within 30 days. We identified 4 longitudinal trajectories of blood glucose, including class 1 (a low initial average blood glucose level with steady trend within 24 hours), class 2 (a high initial average blood glucose with gently decreased trend), class 3 (the highest initial average blood glucose with rapidly decreased trend) and class 4 (a high initial average blood glucose level with the trend that increased at first and then decreased). After adjusting for covariates, an average blood glucose level of ≥200 mg/dL was linked to higher risk of 30-day mortality, comparing to that of <140 mg/dL (HR = 1.80, 95%CI: 1.23–2.63). Comparing to patients whose longitudinal trajectory of blood glucose conformed to class 1, those with class 2 (HR = 2.52, 95%CI: 1.79–3.53) or class 4 (HR = 3.53, 95%CI: 2.07–6.03) seemed to have higher risk of 30-day mortality. Additionally, these associations were also significant in aged ≥60 years old, female, male, NSTEMI, and STEMI subgroups (all P <0.05). A low level of average blood glucose at the ICU admission or reducing blood glucose to a normal level quickly with adequate measures in 24 hours after ICU admission may be beneficial for AMI patients with DM to reduce the risk of 30-day mortality. These findings may provide some information for further exploration on appropriate range of blood glucose changes in clinical practice.

multidisciplinary sciences
Neuromorphic readout integrated circuits and related spike-based image processing

D. Scribner,Tom Petty,Peter Mui

DOI: https://doi.org/10.1109/ISCAS.2017.8050293

2017-05-28

Abstract:Unlike conventional framing cameras, neuromorphic readout integrated circuit (ROIC) outputs contain only asynchronous spikes of +1 or −1 bit signals. This is analogous to a biological retina that outputs ON and OFF pulses. A neuromorphic ROIC has a fast pixel response; outputs sparse data (small changes at the pixel level that represent only motion or temporal changes); and has very low latency. We demonstrate basic spike-based algorithms that can simultaneously: reconstruct full intensity, super-resolution images; and detect and recognize high-speed events that would otherwise not be possible with traditional framing cameras.
Glucose control and outcomes in diabetic and nondiabetic patients treated with targeted temperature management after cardiac arrest

Hyo Jin Bang,Chun Song Youn,Kyu Nam Park,Sang Hoon Oh,Hyo Joon Kim,Soo Hyun Kim,Sang Hyun Park

DOI: https://doi.org/10.1371/journal.pone.0298632

IF: 3.7

2024-02-09

PLoS ONE

Abstract:Hyperglycemia is commonly observed in critically ill patients and postcardiac arrest patients, with higher glucose levels and variability associated with poorer outcomes. In this study, we aim to compare glucose control in diabetic and nondiabetic patients using glycated hemoglobin (HbA1c) levels, providing insights for better glucose management strategies. This retrospective observational study was conducted at Seoul St. Mary's Hospital from February 2009 to May 2022. Blood glucose levels were measured hourly for 48 h after return of spontaneous circulation (ROSC), and a glucose management protocol was followed to maintain arterial blood glucose levels between 140 and 180 mg/dL using short-acting insulin infusion. Patients were categorized into four groups based on diabetes status and glycemic control. The primary outcomes assessed were neurological outcome and mortality at 6 months after cardiac arrest. Among the 332 included patients, 83 (25.0%) had a previous diabetes diagnosis, and 114 (34.3%) had an HbA1c of 6.0% or higher. At least one hyperglycemic episode was observed in 314 patients (94.6%) and hypoglycemia was found in 63 patients (19.0%) during 48 h. After the categorization, unrecognized diabetes was noticed in 51 patients with median HbA1c of 6.3% (interquartile range [IQR] 6.1–6.6). Patients with inadequate diabetes control had the highest initial HbA1c level (7.0%, IQR 6.5–7.8) and admission glucose (314 mg/dL, IQR 257–424). Median time to target glucose in controlled diabetes was significantly shorter with the slowest glucose reducing rate. The total insulin dose required to reach the target glucose level and cumulative insulin requirement during 48 h were different among the categories (p <0.001). Poor neurological outcomes and mortality were more frequently observed in patients with diagnosed diabetes. Occurrence of a hypoglycemic episode during the 48 h after ROSC was independently associated with poor neurologic outcomes (odds ratio [OR] 3.505; 95% confidence interval [CI], 2.382–9.663). Surviving patients following cardiac arrest exhibited variations in glucose hemodynamics and outcomes according to the categories based on their preexisting diabetes status and glycemic condition. Specifically, even experiencing a single episode of hypoglycemia during the acute phase could have an influence on unfavorable neurological outcomes. While the classification did not directly affect neurological outcomes, the present results indicate the need for a customized approach to glucose control based on these categories.

multidisciplinary sciences
Impact of Diabetes in Patients With Acute Myocardial Infarction Undergoing Coronary Artery Bypass Surgery Within 48 Hours

Katharina Huenges,Nele Rainer-Schmidt,Bernd Panholzer,Amke Caliebe,Lennart Hüttmann,Philipp Kolat,Alexander Thiem,Tim Attmann,Sandra Fraund-Cremer,Assad Haneya,Jochen Cremer,Christina Grothusen

DOI: https://doi.org/10.1016/j.hlc.2024.02.014

Abstract:Background: Diabetic patients with coronary artery disease may benefit from elective coronary artery bypass graft (CABG) surgery. It is unknown whether this merit is transferable to patients with acute myocardial infarction (AMI) undergoing surgery. Method: A total of 1,427 patients underwent CABG within 48 hours of being diagnosed with AMI at the current institution between 2001 and 2019. Of these patients, 206 (14.4%) had insulin-dependent diabetes mellitus (IDDM) and 148 (10.4%) had non-insulin dependent diabetes mellitus (NIDDM). Retrospective data analysis was performed. Results: Patients with NIDDM showed the highest perioperative risk profile, with a EuroScore II of 11.6 (±10.3) compared with 7.8 (±8.0) in non-diabetic patients and 8.4 (±7.8) in patients with IDDM (p<0.001). Sub-analysis demonstrated a higher proportion of non-ST-elevation myocardial infarction patients in the NIDDM cohort compared with the IDDM cohort (70.9% vs 56.8%; p=0.005). Postoperatively, NIDDM patients had more sepsis (p<0.01) and longer ventilation times (p<0.001) compared with non-DM and IDDM patients (p<0.01). Wound healing complications were rare, but almost twice as high in NIDDM patients compared with non-DM and IDDM patients (4.7% vs 0.9% vs 2.4%, respectively). The 30-day mortality was highest in the NIDDM cohort (18.3% vs 11.3% vs 7.8%; p=0.012). Analysis of survival for up to 15 years revealed a significantly reduced survival of diabetic patients compared with non-diabetic patients, with lowest survival rates in NIDDM patients (p<0.001). Conclusions: Non-insulin dependent diabetes mellitus patients undergoing CABG within 48 hours of being diagnosed with AMI are at increased risk of short-term and long-term complications. Therefore, this particular group should undergo a careful evaluation concerning the expected risks and benefits of CABG in this setting.
Impact of Glycometabolic Status on Cardiac Function and Recovery in the Early Phase of Acute Myocardial Infarction

Ting-song LIU,Yi-tian CHEN,Shi-sen JIANG,Jian-bin GONG,Qi-gao ZHANG,Yong-ping PENG,Li-jun WANG,Xun-min CHENG,Ying ZOU

DOI: https://doi.org/10.3760/cma.j.issn.1008-6315.2011.02.003

2011-01-01

Abstract:Objective To explore the disparity of severity of cardiac dysfunction and recovery among different glycometabolic patients in the early phase of acute myocardial infarction (AMI) . Methods Consecutive 111 AMI patients without known diabetes underwent continuous glucose monitoring. Patients with different glycometabolic status were compared in terms of cadiac dysfunction and recovery at admission and 3month follow up. Results Compared to patients with normglycemia and transient hyperglycemia, patitents with persistent hyperglycemia were more likely to grade Killip Ⅱ or above,which were 13.3% (4/30) ,33. 3% ( 12/36) ,55. 6% (25/45), 20. 0% ( 6/30), 41.7% ( 15/36 ) and 93.3% (42/45) ( Ps ＜ 0. 01 ). In-hospital left ventricular ejection fraction (LVEF), mitral valve protodiastolic E peak velocities (E) and its ratio to late diastolic (E/A) decreased significantly ( LVEF :0. 52 ± 0. 02,0. 48 ± 0. 01 and 0. 37 ± 0. 02; E: [0. 65 ± 0. 41]m/s,[0.55 ± 0.02] m/s and [0.39 ±0. 12]m/s;E/A:1. 15 ±0.08,1.02 ±0.06 and 0.61 ±0.02,respectively) ( Ps ＜ 0. 01 ), whereas LVESV and WMSI increased significantly ( LVESV: [25.83 ± 0. 51] ml,[31.26 ± 1.23] ml, [37, 72 ± 1.01] ml; WMSI: 1.5 ± 0. 3,1.8 ± 0. 2 and 2. 6 ± 0. 4, respectively) ( Ps ＜ 0. 01 )There months after AMI,patitents with persistent hyperglycemia were more likely to grade NYHA Ⅱ or above compared to patients with normglycemia and transient hyperglycemia [67.5% (27/40), 10.0% (3/30) and 11.8% (4/34),respectively] (P ＜0. 01 ). Echocardiographic recovery was observed in each group,but less in persistent hyperglycemia patients. Conclusion Cardiac function of patients with persistent hyperglycemia suffered more severely from AMI and difficult to recover.
Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects

Enrique Z Fisman,Michael Motro,Alexander Tenenbaum

DOI: https://doi.org/10.1159/000115193

Abstract:Five types of oral antihyperglycemic drugs are currently approved for the treatment of diabetes: biguanides, sulfonylureas, meglitinides, glitazones and alpha-glucosidase inhibitors. We briefly review the cardiovascular effects of the most commonly used antidiabetic drugs in these groups in an attempt to improve knowledge and awareness regarding their influences and potential risks when treating patients with coronary artery disease (CAD). Regarding biguanides, gastrointestinal disturbances such as diarrhea are frequent, and the intestinal absorption of group B vitamins and folate is impaired during chronic therapy. This deficiency may lead to increased plasma homocysteine levels which, in turn, accelerate the progression of vascular disease due to adverse effects on platelets, clotting factors, and endothelium. The existence of a graded association between homocysteine levels and overall mortality in patients with CAD is well established. In addition, metformin may lead to lethal lactic acidosis, especially in patients with clinical conditions that predispose to this complication, such as heart failure or recent myocardial infarction. Sulfonylureas avoid ischemic preconditioning. During myocardial ischemia, they may prevent opening of the ATP-dependent potassium channels, impeding the necessary hyperpolarization that protects the cell by blocking calcium influx. Meglitinides may exert similar effects due to their analogous mechanism of action. During treatment with glitazones, edema has been reported in 5% of patients, and these drugs are contraindicated in diabetics with NYHA class III or IV cardiac status. The long-term effects of alpha-glucosidase inhibitors on morbidity and mortality rates and on diabetic micro- and macrovascular complications is still unknown. Combined sulfonylurea/metformin therapy reveals additive effects on mortality. Four points should be mentioned: (1) the five oral antidiabetic drug groups present proven or potential cardiac hazards; (2) these hazards are not mere 'side effects' but are deeply rooted in the drugs' mechanisms of action; (3) current data indicate that combined glibenclamide/metformin therapy seems to present a special risk and should be avoided in the long-term management of type 2 diabetics with proven CAD, and (4) Non-Insulin Antidiabetic Therapy in Diabetic Cardiac Patients 155 customized antihyperglycemic pharmacological approaches should be investigated for the optimal treatment of diabetic patients with heart disease. New possibilities are represented by incretin mimetic compounds, dipeptidyl peptidase (DPP)-4 inhibitors, inhaled insulin and eventually oral insulin.
Use of clinical practice guidelines in managed care physician groups.

E. Fang,Mittman Bs,S. Weingarten

DOI: https://doi.org/10.1001/ARCHFAMI.5.9.528

1996-10-01

Archives of Family Medicine

Abstract:There is increasing interest in the use of clinical guidelines as a tool to improve the quality and cost-effectiveness of health care. Yet, relatively little data are available regarding the use of guidelines by health care provider organizations. We developed a written descriptive survey investigating the development, implementation, and evaluation of clinical guidelines that was administered to medical directors or their designees from physician medical groups and independent practice associations. Eighty-seven percent of physician organizations were reported to be developing or implementing clinical guidelines. The reasons most often cited for developing clinical guidelines were quality improvement and cost containment. Local expert opinion or judgment was rated as the most important influence in the development of clinical guidelines, followed by medical and scientific literature and externally developed guidelines. Feedback of information was the most popular method of increasing compliance with clinical guidelines, although 19% of physician organizations reported imposing sanctions on physicians who did not use guidelines. Most of the physician organizations surveyed have embraced clinical guidelines. Local development or adaptation of clinical guidelines may be common. There has been disproportionately little attention paid to guideline implementation and to evaluation of guideline effects relative to their development.
Effect of SGLT2 Inhibitors on Post-PCI Outcomes after Acute Myocardial Infarction in Diabetic Patients: A Systematic Review and Meta-Analysis

Xiaoyu Liu,Weifen Wang,Xiaohan Xing

DOI: https://doi.org/10.59958/hsf.7021

IF: 0.699

2024-04-21

The Heart Surgery Forum

Abstract:Background: Acute myocardial infarction (AMI) is related with poor outcomes in patients with diabetes mellitus (DM). Whether diabetic patients with AMI undergoing percutaneous coronary intervention (PCI) benefit from sodium–glucose cotransporter 2 inhibitors (SGLT2i) in terms of cardiovascular mortality, myocardial damage, and left ventricular function is unclear. Methods: Through a comprehensive search in PubMed, EMBASE, and Web of science databases from January 2018 to September 2023, randomized controlled trials were performed to compare SGLT2i with other oral antidiabetic medications in diabetic patients with AMI undergoing PCI. Cardiovascular mortality constituted the primary outcome. Secondary outcomes were high-sensitivity troponin I (hs-TnI) levels, left ventricular ejection fraction (LVEF), and contrast-induced acute kidney injury (CI-AKI). Results: SGLT2i significantly reduced cardiovascular mortality risk versus other antidiabetic agents (hazard ratio (HR): 0.35, 95% confidence interval (CI): 0.21–0.58, p < 0.0001). SGLT2i also lowered hs-TnI levels across all time points (mean difference: –2931 ng/L, p < 0.001). After adjustment for publication bias, this difference was no longer significant. However, peak hs-TnI levels remained significantly lower with SGLT2i (mean difference: –3836 ng/L, p < 0.001). Finally, SGLT2i improved LVEF versus comparators, with a mean difference of –5.00% (95% CI: –6.69 to –3.31, p < 0.001) at hospital discharge. SGLT2i was also associated with 60% lower odds of CI-AKI (odds ratio (OR): 0.40, 95% CI: 0.22–0.75, p = 0.004). Conclusions: Compared with other antidiabetic medications, SGLT2i may lower cardiovascular mortality, infarct size, and prevent left ventricle (LV) systolic dysfunction in diabetic patients with AMI undergoing PCI. The use of SGLT2i in this high-risk group is supported by these findings.

surgery,cardiac & cardiovascular systems
Revascularization for coronary artery disease in diabetes mellitus: Angioplasty, stents and coronary artery bypass grafting

Doron Aronson,Elazer R. Edelman

DOI: https://doi.org/10.1007/s11154-010-9135-3

2010-03-01

Reviews in Endocrine and Metabolic Disorders

Abstract:Patients with diabetes mellitus (DM) are prone to a diffuse and rapidly progressive form of atherosclerosis, which increases their likelihood of requiring revascularization. However, the unique pathophysiology of atherosclerosis in patients with DM modifies the response to arterial injury, with profound clinical consequences for patients undergoing percutaneous coronary intervention (PCI). Multiple studies have shown that DM is a strong risk factor for restenosis following successful balloon angioplasty or coronary stenting, with greater need for repeat revascularization and inferior clinical outcomes. Early data suggest that drug eluting stents reduce restenosis rates and the need for repeat revascularization irrespective of the diabetic state and with no significant reduction in hard clinical endpoints such as myocardial infarction and mortality. For many patients with 1- or 2-vessel coronary artery disease, there is little prognostic benefit from any intervention over optimal medical therapy. PCI with drug-eluting or bare metal stents is appropriate for patients who remain symptomatic with medical therapy. However, selection of the optimal myocardial revascularization strategy for patients with DM and multivessel coronary artery disease is crucial. Randomized trials comparing multivessel PCI with balloon angioplasty or bare metal stents to coronary artery bypass grafting (CABG) consistently demonstrated the superiority of CABG in patients with treated DM. In the setting of diabetes CABG had greater survival, fewer recurrent infarctions or need for re-intervention. Limited data suggests that CABG is superior to multivessel PCI even when drug-eluting stents are used. Several ongoing randomized trials are evaluating the long-term comparative efficacy of PCI with drug-eluting stents and CABG in patients with DM. Only further study will continue to unravel the mechanisms at play and optimal therapy in the face of the profoundly virulent atherosclerotic potential that accompanies diabetes mellitus.

endocrinology & metabolism
Disparities of In-Hospital and Short Term Prognosis of Patients with No History of Diabetes in the Early =phase of Acute Myocardial Infarction

刘挺松,陈一天,江时森,宫剑滨,张启高,彭永平,王立军,程训民,邹莺

DOI: https://doi.org/10.3760/cma.j.issn.1008-6315.2013.05.009

2013-01-01

Abstract:Objective To evaluate the disparities of in-hospital and short term prognosis of patients with different glycometabolic status in the early phase of acute myocardial infarction (AMI).Methods Glycometabolic status of consecutive 111 AMI patients without known diabetes mellitus was evaluated by means of continuous glucose monitoring,72 h blood glucose fluctuations were in continuous tracking from admitting to hospital,as the results assessed,all the patients were divided into AMI early blood sugar fluctuations:normal blood glucose group (NG group),had blood glucose elevated group (TH),and persistent hyperglycemia group (PH group).Patients with different glycometabolic status were compared between term of in-hospital and short term prognosis of AMI.Results There was no significant difference of infarction locations between AMI patients with varying glycometabolic status.Compared with patients of NG and TH,patients with PH presented higher prevalence of malicious arhythmia (10.0％ (3/30),11.1％ (4/36),31.1％ (14/45),x2 =7.347,P ＜ 0.05,cardiogenic shock (3.3％ (1/30),5.6％ (3/36),24.4％ (11/45),x2 =9.686,P ＜ 0.01).Mortality of inhospital(0,5.6％ (3/36),15.6％ (7/45),x2 =6.312,P ＜ 0.05)and after 3 month (0,5.6％ (3/36),17.8％(8/45),x2 =7.715,P ＜0.05)were higher in these patients.Conclusion Persistent hyperglycemia in early stage of AMI was associated with more complications and poor prognosis.

Continuous itaconic acid production by immobilized biocatalysts.

Acute Hyperglycemia-Induced Injury in Myocardial Infarction

Expression Profiles of Long Noncoding RNAs in Cardiac Stem Cells under Hyperglycemic Conditions

Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome

Management of Hyperglycemia in Acute Ischemic Stroke

Importance of measuring glycosylated hemoglobin in patients with myocardial infarction and known diabetes mellitus

Potential value of triple antiplatelet therapy for secondary stroke prevention.

[The Prognostic Value of Admission Blood Glucose Level in Acute Myocardial Infarction after Primary Percutaneous Coronary Intervention].

Hyperglycemia Affects the Prognosis of Acute Myocardial Infarction

Relationship Between Hyperglycaemia at Admission and Prognosis in Patients with Acute Myocardial Infarction: a Retrospective Cohort Study

Lowering glucose to prevent adverse cardiovascular outcomes in a critical care setting

Longitudinal trajectories of blood glucose and 30-day mortality in patients with diabetes mellitus combined with acute myocardial infarction: A retrospective cohort analysis of the MIMIC database

Neuromorphic readout integrated circuits and related spike-based image processing

Glucose control and outcomes in diabetic and nondiabetic patients treated with targeted temperature management after cardiac arrest

Impact of Diabetes in Patients With Acute Myocardial Infarction Undergoing Coronary Artery Bypass Surgery Within 48 Hours

Impact of Glycometabolic Status on Cardiac Function and Recovery in the Early Phase of Acute Myocardial Infarction

Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects

Use of clinical practice guidelines in managed care physician groups.

Effect of SGLT2 Inhibitors on Post-PCI Outcomes after Acute Myocardial Infarction in Diabetic Patients: A Systematic Review and Meta-Analysis

Revascularization for coronary artery disease in diabetes mellitus: Angioplasty, stents and coronary artery bypass grafting

Disparities of In-Hospital and Short Term Prognosis of Patients with No History of Diabetes in the Early =phase of Acute Myocardial Infarction